Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity

Open access
Jack, Clifford R., Wiste, Heather J., Weigand, Stephen D., Knopman, David S., Lowe, Val, Vemuri, Prashanthi, Mielke, Michelle M., Jones, David T., Senjem, Matthew L., Gunter, Jeffrey L., Gregg, Brian E., Pankratz, Vernon S., Petersen, Ronald C. · 2013 · Neurology

Abstract

OBJECTIVE: To estimate the incidence of and to characterize cognitive and imaging findings associated with incident amyloid PET positivity. METHODS: Cognitively normal (CN) participants in the Mayo Clinic Study of Aging who had 2 or more serial imaging assessments, which included amyloid PET, FDG-PET, and MRI at each time point, were eligible for analysis (n = 207). Twelve subjects with Alzheimer disease dementia were included for comparison. RESULTS: Of the 123 CN participants who were amyloid-negative at baseline, 26 met criteria for incident amyloid PET positivity. Compared to the 69 subjects who remained stable amyloid-negative, on average these 26 did not differ on any imaging, demographic, or cognitive variables except amyloid PET (by definition) and task-free functional connectivity, which at baseline was greater in the incident amyloid-positive group. Eleven of the 26 incident amyloid-positive subjects had abnormal hippocampal volume, FDG-PET, or both at baseline. CONCLUSIONS: The incidence of amyloid PET positivity is approximately 13% per year among CN participants over age 70 sampled from a population-based cohort. In 15/26 (58%), incident amyloid positivity occurred prior to abnormalities in FDG-PET and hippocampal volume. However, 11/26 (42%) incident amyloid-positive subjects had evidence of neurodegeneration prior to incident amyloid positivity. These 11 could be subjects with combinations of preexisting non-Alzheimer pathophysiologies and tau-mediated neurodegeneration who newly entered the amyloid pathway. Our findings suggest that both "amyloid-first" and "neurodegeneration-first" biomarker profile pathways to preclinical AD exist.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000435556.21319.e4

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 199

Metadata

Authors
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V., Vemuri, P., Mielke, M. M., Jones, D. T., Senjem, M. L., Gunter, J. L., Gregg, B. E., Pankratz, V. S., & Petersen, R. C.
Venue
Neurology
Published
2013-11-12
Volume
81
Issue
20
Pages
1732-1740
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2157657208
Cited by
199
References
25
FWCI
17.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. https://app.cochat.ai/papers/10.1212/01.wnl.0000435556.21319.e4
The paper
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V., Vemuri, P., Mielke, M. M., Jones, D. T., Senjem, M. L., Gunter, J. L., Gregg, B. E., Pankratz, V. S., & Petersen, R. C. (2013). Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. https://doi.org/10.1212/01.wnl.0000435556.21319.e4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.